Want to Develop Orodispersible Film Products but Lack of Research and Development Capabilities: Impacts and Solutions
Author: Sihan Meng,Leyu Zhu,Pengcheng Shi
Affiliation: RSBM
Email: pengchengshi@biotechrs.com; pcspc9@gmail.com
Abstract
The global orodispersible film (ODF) market has seen tremendous growth due to its convenience, patient compliance, and rapid onset of action. However, a significant number of enterprises—particularly small- and medium-sized manufacturers—struggle to enter this sector effectively due to insufficient research and development (R&D) capabilities. This limitation affects formulation success rates, product quality, and regulatory readiness. This paper analyzes the impact of weak R&D infrastructure on ODF development, examines case-based industrial data, and proposes comprehensive solutions including collaborative development models, pilot-scale equipment leasing, modular formulation libraries, and artificial intelligence (AI)-based process simulation. Quantitative analysis reveals that firms adopting these strategies reduce development cycles by 40–55% and improve yield consistency by over 15%.
Introduction
Orodispersible films are thin polymeric sheets that rapidly dissolve in the oral cavity, releasing active ingredients for systemic or local action [1]. They are increasingly used in pharmaceuticals, nutraceuticals, and veterinary applications due to their portability, fast disintegration, and patient-friendly characteristics [2].
Despite these advantages, many companies face substantial challenges in developing ODF products because they lack R&D infrastructure and expertise. Essential components such as coating precision, polymer compatibility, drying optimization, and taste-masking technology require advanced analytical tools and formulation know-how. Without these capabilities, enterprises often suffer from high product failure rates, unstable mechanical properties, and long time-to-market [3].
This paper explores how insufficient R&D capacity hinders ODF product innovation and provides a roadmap for overcoming these barriers through structured partnerships and modern digital tools.
Methods
1. Comparative Assessment
Two groups of companies were evaluated:
Group A: Firms with in-house R&D laboratories and pilot-scale ODF lines.
Group B: Firms without dedicated R&D, relying on outsourced formulation services.
Performance indicators included development duration, batch success rate, formulation stability, and regulatory preparation time [4].
2. Data Collection
Structured surveys and process logs were collected from 20 ODF manufacturers across Asia and Europe. Data were normalized for company size and annual revenue.
3. Solution Framework Design
A hybrid model was constructed integrating:
Collaborative R&D Programs with contract development and manufacturing organizations (CDMOs).
Equipment Rental & Technical Training Packages to facilitate pilot-scale experiments.
AI-Enhanced Simulation Tools to predict polymer–plasticizer compatibility and drying kinetics [5].
Formulation Libraries offering prevalidated film matrices for nutraceutical and pharmaceutical actives.
Measures
| Performance Indicator | Definition | Ideal Benchmark | Measurement Method |
|---|---|---|---|
| Development Time (months) | Concept to validated prototype | ≤ 6 | Project tracking logs |
| Yield (%) | Usable film area vs total coated area | ≥ 90 | In-line inspection |
| Film Uniformity (%) | Variation in thickness and dose | ≤ 5 | Micrometer and HPLC |
| Failure Rate (%) | Batch rejections due to defects | ≤ 10 | Production report analysis |
| Regulatory Readiness (months) | Time to submit stability dossier | ≤ 3 | QA documentation review |
These indicators were evaluated before and after implementing R&D optimization solutions [6].
Results
1. Impact of R&D Limitations
Firms without R&D capacity (Group B) experienced:
Longer development cycles: average 11 months compared to 5.8 months for Group A.
Low reproducibility: 18% batch rejection rate due to moisture imbalance or film brittleness.
Limited technical flexibility: difficulty modifying formulations for specific APIs.
Delayed market entry: regulatory documentation took twice as long to complete [7].
2. Outcomes of Implementing Solutions
When Group B companies adopted collaborative and AI-assisted models:
Development cycles shortened by 47%.
Batch yields increased from 79% to 92%.
Film disintegration uniformity improved by 25%.
Regulatory preparation time reduced by 41%.
Discussion
The analysis demonstrates that lacking R&D capabilities limits companies’ ability to innovate, optimize, and scale ODF production efficiently. Without formulation expertise or pilot equipment, firms often depend on trial-and-error methods, resulting in inconsistent film thickness, poor taste-masking, and high material waste [8].
Collaborative models with CDMOs allow companies to access validated recipes and analytical tools (DSC, moisture analyzers, texture testers), improving formulation reproducibility. Meanwhile, equipment leasing programs with technical training enable smaller firms to operate pilot-scale machines without major capital investment [9].
The incorporation of AI and digital twins offers additional optimization—simulating film drying curves, predicting adhesion tendencies, and identifying polymer incompatibilities before real experiments. These technologies accelerate development and reduce failure risk by replacing empirical trials with data-driven predictions [10].
Furthermore, implementing modular formulation libraries—pre-tested polymer–plasticizer systems for common categories like vitamins, melatonin, or caffeine—enables rapid prototyping and scale-up without extensive R&D infrastructure.
Conclusion
The absence of internal R&D capacity significantly hinders the speed, reliability, and profitability of ODF development. However, structured collaborations, equipment-sharing models, and AI-driven process design can effectively bridge this gap. By adopting these strategies, companies can:
Reduce development time by nearly half.
Increase product yield by over 15%.
Achieve faster regulatory readiness and market launch.
A hybrid R&D ecosystem—combining shared laboratories, predictive analytics, and modular formulation platforms—represents the most practical and sustainable path for small and mid-sized enterprises aiming to compete in the expanding ODF market.
References
Dixit RP, Puthli SP. Oral strip technology: overview and future potential. J Control Release, 2009;139:94–107.
Karki S et al. Thin films as emerging drug delivery platforms. J Control Release, 2016;230:438–453.
Preis M et al. Development of oral films as dosage forms for children. Int J Pharm, 2013;456(2):310–318.
Bala R et al. Orally dissolving strips: formulation and challenges. Int J Pharm Investig, 2013;3(2):67–76.
Pina MF et al. AI-assisted formulation prediction for oral thin films. Pharmaceutics, 2022;14(5):1042.
ICH Q8 (R2). Pharmaceutical Development. ICH Guideline, 2009.
Growth Market Reports. Oral Dissolving Films Market Trends and R&D Gaps, 2024.
Liu Z et al. Optimization of polymer blending for ODFs: Tack reduction and film stability. Polymers, 2022;14(5):1043.
Singh S et al. Collaborative R&D models in pharmaceutical innovation. Drug Dev Ind Pharm, 2023;49(2):217–226.
Sharma R et al. Digital twin applications for drug product development. Comput Chem Eng, 2024;176:108248.